Results 211 to 220 of about 332,553 (322)

Annual Banned‐Substance Review 17th Edition—Analytical Approaches in Human Sports Drug Testing 2023/2024

open access: yesDrug Testing and Analysis, EarlyView.
Scenarios of drug exposure and administration as well as detection assays for drugs and methods of sports doping published between 2023 and 2024 are critically reviewed and evaluated in context with the Prohibited List 2024 as established by the World Anti‐Doping Agency.
Mario  Thevis   +2 more
wiley   +1 more source

Long‐term outcomes of apixaban as main anticoagulant in patients with HeartMate 3 left ventricular assist devices

open access: yesESC Heart Failure, EarlyView.
Abstract Aims HeartMate 3 (HM3) left ventricular assist devices (LVADs) offer improved haemocompatibility‐related outcomes for end‐stage heart failure patients, facilitating the exploration of alternative anticoagulation therapies beyond warfarin.
Jennifer Jdaidani   +7 more
wiley   +1 more source

Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Dapagliflozin (DAPA), a sodium‐glucose co‐transporter 2 inhibitor, has been shown to reduce cardiovascular mortality among patients with chronic heart failure. We aimed to evaluate the impact on a worsening renal function (WRF) by adding DAPA as compared to standard decongestive therapy with loop diuretics alone.
Shodai Kawanami   +11 more
wiley   +1 more source

CD47 regulates antigen modulation and red blood cell clearance following an incompatible transfusion. [PDF]

open access: yesFront Immunol
Jajosky RP   +7 more
europepmc   +1 more source

Multicentre comparison of various microaxial pump devices as a bridge to durable assist device implantation

open access: yesESC Heart Failure, EarlyView.
In the context of patients with severe heart failure, it is crucial to ensure adequate preconditioning before considering the implantation of dLVAD. Although several types of mechanical circulatory assist devices are available and all offer a significant advantage, the present study suggests that the higher the flow rate provided by the Impella®, the ...
Marta L. Medina   +32 more
wiley   +1 more source

Home - About - Disclaimer - Privacy